-
Product Insights
New![]()
Net Present Value Model: AstraZeneca Plc’s Mitiperstat
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Atai Life Sciences NV’s KUR-101
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Eledon Pharmaceuticals Inc’s Tegoprubart
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BNT-113 in Head And Neck Squamous Cell Carcinoma (HNSC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BNT-113 in Head And Neck Squamous Cell Carcinoma (HNSC) Drug Details: BNT-113 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BNT-151 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BNT-151 in Non-Small Cell Lung Cancer Drug Details: BNT-151 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BNT-151 in Hepatocellular Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BNT-151 in Hepatocellular Carcinoma Drug Details: BNT-151 is under development for the treatment of multiple...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BNT-151 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BNT-151 in Solid Tumor Drug Details: BNT-151 is under development for the treatment of multiple...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BNT-151 in Kidney Cancer (Renal Cell Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BNT-151 in Kidney Cancer (Renal Cell Cancer) Drug Details: BNT-151 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BNT-151 in Head And Neck Squamous Cell Carcinoma (HNSC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BNT-151 in Head And Neck Squamous Cell Carcinoma (HNSC) Drug Details: BNT-151 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BNT-166a in Monkeypox
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BNT-166a in Monkeypox Drug Details: BNT-166a is under development for the prevention of monkeypox infection....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.